157 related articles for article (PubMed ID: 9846027)
1. Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study.
Watanabe S; Pereira J; Hanson J; Bruera E
J Pain Symptom Manage; 1998 Nov; 16(5):323-6. PubMed ID: 9846027
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management.
Paix A; Coleman A; Lees J; Grigson J; Brooksbank M; Thorne D; Ashby M
Pain; 1995 Nov; 63(2):263-269. PubMed ID: 8628593
[TBL] [Abstract][Full Text] [Related]
4. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
5. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
6. Transdermal opioids for cancer pain.
Skaer TL
Health Qual Life Outcomes; 2006 Mar; 4():24. PubMed ID: 16573839
[TBL] [Abstract][Full Text] [Related]
7. [Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
Yamazaki M; Aoki T; Tachibana M; Akashi T
Gan To Kagaku Ryoho; 2006 Feb; 33(2):217-21. PubMed ID: 16484859
[TBL] [Abstract][Full Text] [Related]
8. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
Jackson LD; Wortzman R; Chua D; Selby D
J Oncol Pharm Pract; 2021 Jan; 27(1):238-243. PubMed ID: 32501183
[TBL] [Abstract][Full Text] [Related]
9. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
[TBL] [Abstract][Full Text] [Related]
10. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
Santiago-Palma J; Khojainova N; Kornick C; Fischberg DJ; Primavera LH; Payne R; Manfredi P
Cancer; 2001 Oct; 92(7):1919-25. PubMed ID: 11745266
[TBL] [Abstract][Full Text] [Related]
11. Continuous fentanyl infusion: use in severe cancer pain.
Lenz KL; Dunlap DS
Ann Pharmacother; 1998 Mar; 32(3):316-9. PubMed ID: 9533063
[TBL] [Abstract][Full Text] [Related]
12. [Transdermal route as an alternative to oral administration of opioids in cancer pain].
Burza M; Ginobbi P; Fusco G; Laurenzi L; Tirelli W; Arcuri E
Clin Ter; 1998; 149(4):277-80. PubMed ID: 9866889
[TBL] [Abstract][Full Text] [Related]
13. Management of cancer-related pain with transdermal fentanyl.
Leelanuntakit S
J Med Assoc Thai; 1996 Jun; 79(6):341-6. PubMed ID: 8855606
[TBL] [Abstract][Full Text] [Related]
14. Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Sittl R; Nuijten M; Poulsen Nautrup B
Clin Ther; 2006 Aug; 28(8):1144-1154. PubMed ID: 16982291
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of fentanyl patch in home palliative care].
Yoshizawa A; Gyouda Y; Ishiguro T; Yoshizawa T; Yoshida S
Gan To Kagaku Ryoho; 2003 Dec; 30(1 Suppl):129-31. PubMed ID: 15311783
[TBL] [Abstract][Full Text] [Related]
16. [Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan].
Hashizume T; Tomiyasu S; Yomiya K; Yoshimoto T; Harada A; Matoba M;
Gan To Kagaku Ryoho; 2007 Jun; 34(6):897-902. PubMed ID: 17570968
[TBL] [Abstract][Full Text] [Related]
17. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
[TBL] [Abstract][Full Text] [Related]
18. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
20. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
